Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Oyster Point Pharma, a clinical-stage biopharmaceutical company, has successfully closed a public offering of 4,312,500 shares of common stock at $28.00 each, raising approximately $120.8 million. This includes the full exercise of underwriters’ options for 562,500 additional shares. J.P. Morgan, Cowen, and Piper Sandler co-managed the offering. The funds are intended to support the development of OC-01 nasal spray, aimed at treating dry eye disease, which affects over 30 million Americans. This offering follows the effective registration statement declared on May 14, 2020.

Positive

• Raised approximately $120.8 million through the offering to support product development.
• OC-01 nasal spray targets a significant market with over 30 million Americans affected by dry eye disease.

Negative

• The public offering may lead to shareholder dilution as more shares are now in circulation.

PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the closing of a public offering of 4,312,500 shares of its common stock at a price to the public of $28.00 per share, which includes 562,500 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares were offered by Oyster Point Pharma. The aggregate gross proceeds to Oyster Point Pharma from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $120.8 million.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Sandler & Co. acted as joint book-running managers for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus, when available, may be obtained for free from the offices of J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by emailing prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at (800) 747-3924 or via email at prospectus@psc.com.

A registration statement relating to the offering has been filed with the United States Securities and Exchange Commission and was declared effective on May 14, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).

About Dry Eye Disease
Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. An estimated 16 million U.S. adults have been diagnosed with dry eye disease, a multifactorial condition of the ocular surface characterized by disruption of the tear film. A healthy tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components to reduce the risk of infection, and creates a smooth surface that contributes refractive power for clear vision. Dry eye disease can have a significant impact on a person’s day-to-day quality of life, as it can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.

Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact
Jeffrey Nau PhD, MMS
President and CEO
media@oysterpointrx.com

FAQ

What was the share price for Oyster Point Pharma's recent public offering?

The share price for the recent public offering was $28.00 per share.

How many shares did Oyster Point Pharma offer in the recent public offering?

Oyster Point Pharma offered a total of 4,312,500 shares.

What are the intended uses for the funds raised in the Oyster Point Pharma offering?

The funds will be used to support the development of OC-01 nasal spray for treating dry eye disease.

Who managed the public offering for Oyster Point Pharma?

J.P. Morgan Securities, Cowen and Company, and Piper Sandler acted as joint book-running managers.

What is the significance of OC-01 nasal spray in the context of dry eye disease?

OC-01 nasal spray aims to address an unmet need for effective therapies for the over 30 million Americans suffering from dry eye disease.